Please try another search
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Name | Age | Since | Title |
---|---|---|---|
Linda Cathavina Bain | 53 | 2020 | Independent Director |
John G. Houston | 63 | 2017 | Chairperson, CEO & President |
Edward Moore Kennedy | 62 | 2018 | Independent Director |
Michelle Arkin | - | 2023 | Member of Scientific Advisory Board |
Everett V. Cunningham | 58 | 2022 | Independent Director |
Sunil Agarwal | 54 | 2023 | Independent Director |
Benjamin G. Neel | - | 2019 | Member of Scientific Advisory Board |
Briggs W. Morrison | 64 | 2018 | Lead Independent Director |
Laurie Smaldone Alsup | 70 | 2019 | Independent Director |
Lennart Mucke | - | 2019 | Member of Scientific Advisory Board |
Leslie V. Norwalk | 59 | 2019 | Independent Director |
Adam L. Boxer | - | 2019 | Member of Scientific Advisory Board |
John D. Young | 60 | 2022 | Independent Director |
Bradley T. Hyman | - | 2022 | Member of Scientific Advisory Board |
Lillian L. Siu | - | 2019 | Member of Scientific Advisory Board |
Susan Kaech | - | 2022 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review